{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T22:59:03Z","timestamp":1766012343160},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>In Western Europe, currently only Ireland and Portugal continue to provide universal neonatal bacillus Calmette-Gu\u00e9rin (BCG) vaccination programs, despite not being considered as high tuberculosis (TB) incidence countries. Other European countries only vaccinate infants considered at high risk of contracting TB. We evaluated the cost-effectiveness of selective BCG vaccination compared with strategies of universal and no vaccination.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>An economic model was used to simulate a cohort from birth to life expectancy, taking the perspective of the publicly funded healthcare system. BCG protection was modeled to last 15 years. International vaccine efficacy data were combined with Irish epidemiologic and cost data. The model took into account long-term sequelae associated with TB meningitis and severe adverse reactions relating to the BCG vaccine. A fully probabilistic model was used to incorporate uncertainty across all parameters.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>At \u20ac139,557 per quality-adjusted life year, selective vaccination was not cost-effective relative to a program of no vaccination. The incremental cost-effectiveness of universal vaccination was \u20ac2.55 million per quality-adjusted life year relative to selective vaccination. There was substantial uncertainty regarding the effectiveness of BCG vaccination. The cost-effectiveness of selective vaccination could be substantially improved by reducing the cost of administering the vaccine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In the absence of changes to other aspects of TB control, a switch to selective vaccination will result in increased cases of childhood TB. Although not considered cost-effective, selective vaccination may be preferable to no vaccination until other changes to TB control may be implemented to reduce the risk of TB in children.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000001891","type":"journal-article","created":{"date-parts":[[2018,2,11]],"date-time":"2018-02-11T12:53:22Z","timestamp":1518353602000},"page":"759-767","source":"Crossref","is-referenced-by-count":6,"title":["Economic Evaluation of Selective Neonatal Bacillus Calmette-Gu\u00e9rin Vaccination of High-risk Infants in Ireland"],"prefix":"10.1097","volume":"37","author":[{"given":"Conor","family":"Teljeur","sequence":"first","affiliation":[{"name":"Health Information and Quality Authority"},{"name":"Trinity College Dublin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick S.","family":"Moran","sequence":"additional","affiliation":[{"name":"Health Information and Quality Authority"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Harrington","sequence":"additional","affiliation":[{"name":"Health Information and Quality Authority"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina","family":"Butler","sequence":"additional","affiliation":[{"name":"Our Lady\u2019s Children\u2019s Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Corcoran","sequence":"additional","affiliation":[{"name":"National Immunisation Office"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Health Protection Surveillance Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cara","family":"Usher","sequence":"additional","affiliation":[{"name":"National Centre for Pharmacoeconomics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darina","family":"O\u2019Flanagan","sequence":"additional","affiliation":[{"name":"Health Protection Surveillance Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Connolly","sequence":"additional","affiliation":[{"name":"National Immunisation Advisory Committee, Dublin, Ireland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1ir\u00edn","family":"Ryan","sequence":"additional","affiliation":[{"name":"Health Information and Quality Authority"},{"name":"Trinity College Dublin"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17370","article-title":"Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Gu\u00e9rin vaccination against tuberculosis.","volume":"17","author":"Abubakar","year":"2013","journal-title":"Health Technol Assess"},{"issue":"suppl 3","key":"R2-20230912","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1086\/314072","article-title":"Preventing tuberculosis with bacillus Calmette-Gu\u00e9rin vaccine: a meta-analysis of the literature.","volume":"31","author":"Brewer","year":"2000","journal-title":"Clin Infect Dis"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jama.1994.03510330076038","article-title":"Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature.","volume":"271","author":"Colditz","year":"1994","journal-title":"JAMA"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"e1001012","DOI":"10.1371\/journal.pmed.1001012","article-title":"The BCG World Atlas: a database of global BCG vaccination policies and practices.","volume":"8","author":"Zwerling","year":"2011","journal-title":"PLoS Med"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1586\/erv.11.197","article-title":"A review of the literature on the economics of vaccination against TB.","volume":"11","author":"Tu","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"R6-20230912","first-page":"22","article-title":"A cost-effectiveness analysis of universal versus selective immunization with Mycobacterium bovis bacille Calmette-Gu\u00e9rin in Finland.","volume":"7","author":"Hersh","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"A393","DOI":"10.1016\/j.jval.2012.08.1114","article-title":"Cost-effectiveness analysis of the primovaccination of newborns against tuberculosis in Slovakia.","volume":"15","author":"Marusakova","year":"2012","journal-title":"Value Health"},{"key":"R8-20230912","first-page":"2","article-title":"Cancelling obligatory mass vaccination of newborns against TB in Slovakia: predicted development.","volume":"6","author":"Marusakova","year":"2012","journal-title":"Univ Rev"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0962-8479(94)90003-5","article-title":"Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guerin (BCG) in countries with a low prevalence of tuberculosis. A statement of the International Union Against Tuberculosis and Lung Disease.","volume":"75","year":"1994","journal-title":"Tuber Lung Dis"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13690-016-0141-0","article-title":"Evaluating the neonatal BCG vaccination programme in Ireland.","volume":"74","author":"Usher","year":"2016","journal-title":"Arch Public Health"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1017\/S0950268815000138","article-title":"Tuberculosis incidence in the Irish Traveller population in Ireland from 2002 to 2013.","volume":"143","author":"O\u2019Toole","year":"2015","journal-title":"Epidemiol Infect"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/ese.16.12.19826-en","article-title":"Assessing the effect of foreign travel and protection by BCG vaccination on the spread of tuberculosis in a low incidence country, United Kingdom, October 2008 to December 2009.","volume":"16","author":"Abubakar","year":"2011","journal-title":"Euro Surveill"},{"key":"R15-20230912","first-page":"255","article-title":"Protective vaccination against tuberculosis with special reference to BCG vaccination.","volume":"58","author":"Aronson","year":"1948","journal-title":"Am Rev Tuberc"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0041-3879(49)80055-9","article-title":"BCG vaccination of Indian infants in Saskatchewan.","volume":"30","author":"Ferguson","year":"1949","journal-title":"Tubercle"},{"key":"R17-20230912","first-page":"525","article-title":"Environmental influence on immunity due to B.C.G. vaccination.","volume":"13","author":"Mehta","year":"1976","journal-title":"Indian Pediatr"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0022-3476(45)80195-6","article-title":"Ten years\u2019 experience with BCG (experimental and clinical).","volume":"26","author":"Rosenthal","year":"1945","journal-title":"J Pediatr"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1183\/09031936.00113413","article-title":"Bacille Calmette-Gu\u00e9rin vaccination: the current situation in Europe.","volume":"43","author":"Dara","year":"2014","journal-title":"Eur Respir J"},{"issue":"suppl 1","key":"R21-20230912","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2249.2009.03954.x","article-title":"The European internet-based patient and research database for primary immunodeficiencies: results 2006\u20132008.","volume":"157","author":"Gathmann","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10875-005-0360-9","article-title":"Primary immunodeficiency disorders in the Republic of Ireland: first report of the national registry in children and adults.","volume":"25","author":"Abuzakouk","year":"2005","journal-title":"J Clin Immunol"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jaci.2014.02.028","article-title":"BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies.","volume":"133","author":"Marciano","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"R25-20230912","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4103\/0019-5359.110911","article-title":"Study of impact of antitubercular therapy on quality of life.","volume":"66","author":"Balgude","year":"2012","journal-title":"Indian J Med Sci"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s11136-012-0329-x","article-title":"A systematic review and meta-analysis of the impact of tuberculosis on health-related quality of life.","volume":"22","author":"Bauer","year":"2013","journal-title":"Qual Life Res"},{"key":"R28-20230912","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1016\/S0264-410X(03)00562-0","article-title":"Invasive meningococcal and pneumococcal disease in Switzerland: cost-utility analysis of different vaccine strategies.","volume":"21","author":"Ruedin","year":"2003","journal-title":"Vaccine"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1016\/j.vaccine.2010.05.048","article-title":"Single versus multi-dose vaccine vials: an economic computational model.","volume":"28","author":"Lee","year":"2010","journal-title":"Vaccine"},{"key":"R33-20230912","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1016\/j.vaccine.2014.07.096","article-title":"Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada.","volume":"32","author":"Tu","year":"2014","journal-title":"Vaccine"},{"key":"R35-20230912","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/EDE.0b013e31819e3c1a","article-title":"Targeted BCG vaccination against severe tuberculosis in low-prevalence settings: epidemiologic and economic assessment.","volume":"20","author":"Altes","year":"2009","journal-title":"Epidemiology"},{"key":"R36-20230912","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/ije\/30.2.380","article-title":"Economic evaluation of universal BCG vaccination of Japanese infants.","volume":"30","author":"Rahman","year":"2001","journal-title":"Int J Epidemiol"},{"key":"R37-20230912","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/0962-8479(92)90149-E","article-title":"The impact of changing BCG coverage on tuberculosis incidence in Swedish-born children between 1969 and 1989.","volume":"73","author":"Romanus","year":"1992","journal-title":"Tuber Lung Dis"},{"key":"R38-20230912","doi-asserted-by":"crossref","first-page":"19824","DOI":"10.2807\/ese.16.12.19824-en","article-title":"Assessing BCG vaccination coverage and incidence of paediatric tuberculosis following two major changes in BCG vaccination policy in France.","volume":"16","author":"Guthmann","year":"2011","journal-title":"Euro Surveill"},{"key":"R39-20230912","doi-asserted-by":"crossref","first-page":"21064","DOI":"10.2807\/1560-7917.ES2015.20.11.21064","article-title":"Impact of the BCG vaccination policy on tuberculous meningitis in children under 6 years in metropolitan France between 2000 and 2011.","volume":"20","author":"Van Bui","year":"2015","journal-title":"Euro Surveill"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201808000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:14:32Z","timestamp":1694556872000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201808000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001891","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}